Immune checkpoint blockage targeting programmed cell death 1 (PD-1) on T cell such as nivolumab and pembrolizumab has been emerging, and remains as backbone in GC immunotherapy and serve as a promising treatment strategy for advanced GC patients. Here, PDCD1 is linked to gastric cancer.